**NEJM Evidence**, a new monthly digital journal from NEJM Group, publishes innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.

**AIMS AND SCOPE**

The volume of clinical research continues to grow, yet the standards to establish and validate claims, especially as related to clinical practice, have not followed suit. **NEJM Evidence** expands the corpus of published research with a focus on providing more context and critical evaluation of the methods and results to support clinical decision-making, and does so in a way that respects the time and commitment of the practitioner.

**NEJM Evidence** seeks to advance clinical trial research and clinical practice by:

- Publishing high-quality studies from the frontline of medical research.
- Encouraging the medical community to take new approaches to clinical trial design and execution that yield more powerful clinical evidence.
- Sparking debate and conversation around areas of medicine where clinical decisions are made without sufficient evidence.
- Challenging physicians to engage more meaningfully with clinical evidence.

Adhering to rigorous NEJM Group peer-review standards, **NEJM Evidence** publishes:

- Original research, clinical trials, and other studies (e.g., first-in-human trials, epidemiology, meta-analyses) that validate or challenge prior findings.
- Standard reviews, systematic reviews, and others that contextualize research findings to accelerate clinical adoption of new evidence.
- Case studies and reviews of clinical trial methodology that enhance understanding of trial strengths and weaknesses.
- Curbside Consult series to address common issues in delivering patient care, and case presentations in a morning report format.

Unique content and features include:

- **Tomorrow’s Trial**, a series of short pieces that highlight accepted practices lacking solid evidence and inviting clinician readers to propose clinical trials to fill those gaps.
- **Patient Platform**, in which patients who have been in a clinical trial or part of a research study share their thoughts on their experience.
- **Trial by Fire**, a podcast that features 5-minute discussions between a person associated with a published trial and a critic of the trial.
- **Stats, STAT!**, a brief animated video explaining a statistical concept based on a statistical review.
The process of generating evidence is a key area of focus for *NEJM Evidence*. We encourage readers to evaluate the reasoning behind the complex decisions that investigators make in trial design and execution and to assess the quality of evidence produced in trials. Our goal is to build a community that takes a rigorous approach to evaluating evidence and assessing its impact on clinical decision-making.

*NEJM Evidence* also guides readers toward a deeper understanding of the statistical methods used in trials. We provide concise, digestible explanations of research methods to inform the interpretation of the resulting data. In addition, we introduce readers to emerging statistical methods and types of data that will play an increasingly prominent role in future trials.

*NEJM Evidence* publishes content relevant across medical disciplines, advancing the discussion about how we generate evidence that informs patient care. Physician-scientists, general medicine clinicians, subspecialty physicians, clinical trialists, and basic scientists will all benefit from this publication.

**EDITORIAL TEAM** *NEJM Evidence* physician-editors are dedicated to advancing clinical medicine and working with clinicians and investigators to improve clinical trial studies.

**EDITOR-IN-CHIEF**
Jeffrey M. Drazen, MD

Jeff joined the *New England Journal of Medicine* (NEJM) as Editor-in-Chief in 2000 and was appointed Editor-in-Chief, NEJM Group, in 2012, serving in both roles until 2019. He is now NEJM Group Editor and Editor-in-Chief of *NEJM Evidence*.

**STATISTICAL EDITOR**
Sharon-Lise T. Normand, MSc, PhD

Sharon-Lise joined NEJM as a Statistical Editor in 2017. She is the S. James Adelstein Professor of Health Care Policy in the Department of Health Care Policy at Harvard Medical School and a Professor in the Department of Biostatistics at the Harvard T.H. Chan School of Public Health.

**EXECUTIVE EDITOR**
Chana A. Sacks, MD, MPH

Chana joined NEJM as a 2014-2015 NEJM Editorial Fellow and has served as Editor of Images in Clinical Medicine since 2016. She is Co-Director of the Massachusetts General Hospital (MGH) Center for Gun Violence Prevention and a Clinician-Investigator in the MGH’s Division of General Internal Medicine and Mongan Institute, where she is also a Health Policy Researcher.

**DEPUTY EDITOR**
C. Corey Hardin, MD, PhD

Corey joined NEJM as Reviews Editor in 2021. He is an Assistant Professor of Medicine at Harvard Medical School and a member of the joint Harvard-MIT Program in Health Sciences and Technology faculty.

**2021-2022 NEJM EDITORIAL FELLOW**
Katherine S. Takvorian, MD, MPH

Prior to joining NEJM, Kate served as an MGH Resident-Investigator in cardiometabolics and heart failure. She completed her residency in Internal Medicine at MGH, where she currently works as a Hospitalist.

**EDITORIAL COORDINATOR**
Neil Galloway

Neil joined NEJM in 2012, working in both manuscript editing and editorial operations. In 2016, he became the Executive Assistant to Jeffrey Drazen. He holds a BA in strategic communications from The Ohio State University.

---

**LAUNCHING JANUARY 2022**

*NEJM Evidence* is accepting submissions. Visit [https://evidence.nejm.org](https://evidence.nejm.org) for more information.

Follow *NEJM Evidence* on Twitter: @NEJMEvidence

Institutional subscriptions are available. Contact the sales team at institutionsales@nejm.org.